(8a) Pre-Clinical Manufacturing and Process Intensification of a Subunit Vaccine for COVID-19 (Faculty Candidate)
AIChE Annual Meeting
Monday, November 16, 2020 - 8:00am to 8:15am
We expressed the SARS-CoV-2 receptor binding domain (RBD) in K. phaffii. Speed of the yeast host, combined with InSCyT, our benchtop scale, continuous, end-to-end manufacturing platform, enabled purification and characterization of RBD in quantities and qualities sufficient for pre-clinical studies in less than one month. During pre-clinical studies, we used modern diagnostic tools like RNAseq and rapid genome engineering tools like CRISPR to improve specific and volumetric productivity of our host and process by >5x. Our intensified process demonstrates rapid development of a manufacturing process compatible with existing centralized and distributed manufacturing platforms, and within the low cost necessary for global distribution.